Pembrolizumab for Carcinoma, Non-Small-Cell Lung

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Carcinoma, Non-Small-Cell Lung
Pembrolizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at the efficacy and safety of two different drugs in combination with pembrolizumab for people with NSCLC who have been treated with anti-PD-L1 therapy before.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to approximately 27 months

Month 24
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Month 27
Number of Participants Who Experience One or More Adverse Events (AEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Pembrolizumab + MK-0482
1 of 3
Pembrolizumab + MK-5890
1 of 3
Pembrolizumab + MK-4830
1 of 3

Experimental Treatment

135 Total Participants · 3 Treatment Groups

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Pembrolizumab + MK-0482Experimental Group · 2 Interventions: Pembrolizumab, MK-0482 · Intervention Types: Biological, Biological
Pembrolizumab + MK-5890Experimental Group · 4 Interventions: diphenhydramine, Pembrolizumab, MK-5890, acetaminophen · Intervention Types: Drug, Biological, Biological, Drug
Pembrolizumab + MK-4830Experimental Group · 2 Interventions: Pembrolizumab, MK-4830 · Intervention Types: Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diphenhydramine
FDA approved
Pembrolizumab
FDA approved
Acetaminophen
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 27 months

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,658 Previous Clinical Trials
4,955,007 Total Patients Enrolled
146 Trials studying Carcinoma, Non-Small-Cell Lung
44,047 Patients Enrolled for Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,579,037 Total Patients Enrolled
60 Trials studying Carcinoma, Non-Small-Cell Lung
20,414 Patients Enrolled for Carcinoma, Non-Small-Cell Lung
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,623 Previous Clinical Trials
7,938,272 Total Patients Enrolled
65 Trials studying Carcinoma, Non-Small-Cell Lung
23,372 Patients Enrolled for Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to complete all screening procedures within the 35-day screening window.
You are a woman of childbearing potential (WOCBP) or a WOCBP who agrees to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.
You have non-squamous NSCLC and are not eligible for an approved targeted therapy.
You have progressive disease (PD) during/after platinum doublet chemotherapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: November 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.